Nathalia Lopez Duarte

Dr. Nathalia Lopez Duarte

Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
+1
orcid
MD, PhD

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
EOElen Oliveira
Elen Oliveira
TBThiago S. Bacelar
Thiago S. Bacelar
JCJuana Ciudad
Juana Ciudad
MRMaria Cecília M. Ribeiro
Maria Cecília M. Ribeiro
DGDaniela R.N. Garcia
Daniela R.N. Garcia
ECElaine Sobral da Costa
Elaine Sobral da Costa
// Elen Oliveira 1, 2 , Thiago S. Bacelar 2 , Juana Ciudad 3 , Maria Cecília M. Ribeiro 4 , Daniela R.N. Garcia 1, 5 , Lukasz Sedek 6 , Simone F. Maia 7 , Daniel B. Aranha 1 , Indyara C. Machado 8 , Arissa Ikeda 9 , Bianca F. Baglioli 10 , Nathalia Lopez-Duarte 2 , Lisandra A. C. Teixeira 1, 2 , Tomasz Szczepanski 6 , Maria Luiza M. Silva 5 , Marcelo G.P. Land 1, 2 , Alberto Orfao 3, * , Elaine S. Costa 1, 2, * 1 Clinical Medicine Postgraduate Program, College of Medicine, Rio de Janeiro Federal University (UFRJ), Rio de Janeiro, Brazil 2 Cytometry Service, Institute of Pediatrics and Puericulture Martagão Gesteira (IPPMG), UFRJ, Rio de Janeiro, Brazil 3 Departament of Medicine and Cytometry Service, Cancer Research Center (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca (USAL), Salamanca, Spain 4 Cytogenetics Service, IPPMG-UFRJ and Polo Xerém-UFRJ, Rio de Janeiro, Brazil 5 Cytogenetics Department, Bone Marrow Transplantation Unit and Oncology Post Graduation Program, National Cancer Institute (INCa), Rio de Janeiro, Brazil 6 Department of Pediatric Hematology/Oncology, Medical University of Silesia, Zabrze, Poland 7 Service of Pediatric Hematology, Federal Lagoa Hospital (HFL), Rio de Janeiro, Brazil 8 Service of Pediatric Hematology, São José do Avaí Hospital (HSJA), Itaperuna, Rio de Janeiro, Brazil 9 Service of Pediatric Hematology/Oncology, Servidores do Estado Federal Hospital (HSE), Rio de Janeiro, Brazil 10 Service of Pediatric Hematology, Children’s Cancer Hospital of Barretos, Barretos, São Paulo, Brazil * These authors contributed equally to this work Correspondence to: Elaine S. Costa, e-mail: elainesc.ufrj@gmail.com Alberto Orfao, e-mail: orfao@usal.es Keywords: B-cell precursor acute lymphoblastic leukemia, residual hematopoiesis, altered neutrophil immunophenotype, multiparameter flow cytometry, childhood Received: December 22, 2015 Accepted: March 02, 2016 Published: March 25, 2016 ABSTRACT An increasing number of evidences suggest a genetic predisposition in acute lymphoblastic leukemia (ALL) that might favor the occurrence of the driver genetic alterations. Such genetic background might also translate into phenotypic alterations of residual hematopoietic cells. Whether such phenotypic alterations are present in bone marrow (BM) cells from childhood B-cell precursor (BCP)-ALL remains to be investigated. Here we analyzed the immunophenotypic profile of BM and peripheral blood (PB) maturing/matured neutrophils from 118 children with BCP-ALL and their relationship with the features of the disease. Our results showed altered neutrophil phenotypes in most (77%) BCP-ALL cases. The most frequently altered marker was CD10 (53%), followed by CD33 (34%), CD13 (15%), CD15/CD65 (10%) and CD123 (7%). Of note, patients with altered neutrophil phenotypes had younger age ( p = 0.03) and lower percentages of BM maturing neutrophils ( p = 0.004) together with greater BM lymphocyte ( p = 0.04), and mature B-cell ( p = 0.03) counts. No significant association was found between an altered neutrophil phenotype and other disease features. These findings point out the potential existence of an altered residual hematopoiesis in most childhood BCP-ALL cases.

21 August 2024 in Cancers
Verified
Journal Article
Open access
PDF file
PHPatricia Regina Cavalcanti Barbosa Horn
Patricia Regina Cavalcanti Barbosa Horn
MRMarilza de Moura Ribeiro-Carvalho
Marilza de Moura Ribeiro-Carvalho
AAAlice Maria Boulhosa de Azevedo
Alice Maria Boulhosa de Azevedo
ASAdriana Martins de Sousa
Adriana Martins de Sousa
SFSimone Faria
Simone Faria
MOMaria Helena Ornellas
Maria Helena Ornellas
Introduction: The objective of the current study was to determine the survival probabilities of children and adolescents with acute lymphocytic leukemia treated with adapted Berlin–Frankfurt–Münster (BFM) protocols and compare our results with the original BFM reports. Methods: This retrospective study included 695 patients up to 19 years old treated with adapted BFM protocols between 1997 and 2018 in four hospitals in Rio de Janeiro. The 1997–2007 and 2008–2018 cohorts were analyzed separately. Results: More than half of the patients were stratified into the high-risk BFM classification. Overall and event-free survivals were, in the 1997–2007 period, respectively, 88% and 80% (BFM standard risk group—SRG), 75% and 67% (intermediate risk group—IRG), and 48% and 33% (high-risk group—HRG). The corresponding numbers for the 2008–2018 period were 93% and 84% (SRG), 75% and 63% (IRG), and 64% and 57% (HRG). In the second period, both the OS (HR = 0.71, p = 0.011) and EFS (HR = 0.62, p < 0.001) were higher. Except for the intermediate-risk group, the latter results are comparable to the BFM. Conclusion: The BFM protocol adaptations can be safely implemented in developing countries, accounting for local specificities.

12 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Nathalia Lopez DuarteNathalia Lopez Duarte
Nathalia Lopez Duarte
ABAna Paula Silva Bueno
Ana Paula Silva Bueno
Bárbara Sarni SanchesBárbara Sarni Sanches
Bárbara Sarni Sanches
GRGabriella Alves Ramos
Gabriella Alves Ramos
JSJulia Maria Bispo dos Santos
Julia Maria Bispo dos Santos
Marcelo Gerardin Poirot LandMarcelo Gerardin Poirot Land
Marcelo Gerardin Poirot Land
The incidence of cancer in children living with HIV (CLWH) is high and lymphomas are the most common type of cancer in this population. The combined antiretroviral therapy (cART) changed the natural history of HIV infection. To determine the incidence and profile of these CLWH malignancies in Rio de Janeiro (RJ), Brazil, we conducted a retrospective and observational study of vertically infected CLWH, ranging from 0–20 incomplete years, from 1995 to 2018, at five reference centers. The study period was divided into three eras in accordance with the widespread use of cART in Brazil. 1306 patients were included. Of the 25 lymphomas found, 19 were AIDS-defining malignancies (ADM); 6 were non-AIDS-defining malignancies (NADM). The incidence rate (IR) of lymphoma developing was 1.70 per 1000 children-year (95% CI 1.09–2.50). ADM development IR decreased from 2.09–1.75–0.19 per 1000 children-year (p < 0.001) through cART eras. Cumulative Nelson–Aalen hazards of developing ADM over a 20-year period were 3.73% in the Early-cART era, 3.07% in the Mid-cART era, and 0.32% in the Late-cART era (p = 0.013). This study demonstrates the IR of lymphoma in CLWH in RJ, Brazil, as well as the benefit of cART in reducing ADM and death occurrence in the Post-cART era.

14 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Nathalia Lopez DuarteNathalia Lopez Duarte
Nathalia Lopez Duarte
ABAna Paula Silva Bueno
Ana Paula Silva Bueno
Bárbara Sarni SanchesBárbara Sarni Sanches
Bárbara Sarni Sanches
GRGabriella Alves Ramos
Gabriella Alves Ramos
JSJulia Maria Bispo dos Santos
Julia Maria Bispo dos Santos
Marcelo Gerardin Poirot LandMarcelo Gerardin Poirot Land
Marcelo Gerardin Poirot Land
Lymphomas related to HIV are generally aggressive and have a poor prognosis, despite the use of combined antiretroviral therapy (cART) and effective chemotherapy treatment. To determine survival and prognostic factors in children and adolescents living with HIV (CLWH) in Rio de Janeiro (RJ), Brazil, who developed lymphomas, we performed a retrospective and observational study of vertically infected CLWH aged from 0 to 20 incomplete years during1995 to 2018 at five reference centers for cancer and HIV/AIDS treatment. Of the 25 lymphomas, 19 were AIDS-defining malignancies (ADM) and 6 were non-AIDS-defining malignancies (NADM). The 5-year overall survival (OS) and 5-year event-free survival (EFS) probabilities were both 32.00% (95% CI = 13.72–50.23%), and the 5-year disease-free survival (DFS) probability was 53.30% (95% CI = 28.02–78.58%). In the multivariate Cox regression analysis, performance status 4 (PS 4) was considered a poor prognostic factor for OS (HR 4.85, 95% CI = 1.81–12.97, p = 0.002) and EFS (HR 4.95, 95% CI = 1.84–13.34, p = 0.002). For the DFS, higher CD4+ T-cell counts were considered a better prognostic factor (HR 0.86, 95% CI = 0.76–0.97, p = 0.017) in the multivariate Cox regression analysis. This study demonstrates, for the first time, survival and prognostic factors for CLWH who developed lymphomas in RJ, Brazil.

2 December 2024 in Revista Eletrônica Acervo Saúde
Verified
Journal Article
Closed access
GFGabriel de Moura Fernandes
Gabriel de Moura Fernandes
IFIsabela Alcântara Freitas
Isabela Alcântara Freitas
LVLucia Helena Ferreira Vasconcelos
Lucia Helena Ferreira Vasconcelos
DODanielle Furtado de Oliveira
Danielle Furtado de Oliveira
Nathalia Lopez DuarteNathalia Lopez Duarte
Nathalia Lopez Duarte
Objetivo: Analisar as principais complicações infecciosas no pós-operatório de transplante hepático e suas respectivas profilaxias, com foco nas infecções bacterianas, fúngicas, virais, parasitárias e por organismos multirresistentes. Revisão bibliográfica: As infecções bacterianas são frequentemente causadas por patógenos como Staphylococcus aureus e Pseudomonas aeruginosa, e a profilaxia para estas doenças inclui o uso de antibióticos perioperatórios e medidas de controle de infecção hospitalar. As infecções fúngicas, com destaque para os fungos Candida spp. e Aspergillus spp., são prevenidas com antifúngicos profiláticos e controle ambiental rigoroso. Infecções virais como as causadas pelo citomegalovírus (CMV), vírus de Epstein-Barr (EBV) e as hepatites B e C exigem monitoramento contínuo e profilaxia antiviral. As infecções parasitárias, embora menos comuns, podem ser graves e requerem profilaxia específica para parasitas como Toxoplasma gondii e Strongyloides stercoralis. Infecções por organismos multirresistentes representam um desafio crescente, com necessidade de estratégias de controle de infecção rigorosas e uso criterioso de antibióticos. Considerações finais: O estudo destaca a importância de uma abordagem multidisciplinar e integrada para o manejo das infecções no pós-operatório de transplante hepático, embora a resistência crescente aos antimicrobianos apresente uma limitação significativa para o tratamento eficaz.

2 December 2024 in Revista Eletrônica Acervo Saúde
Verified
Journal Article
Open access
PDF file
GCGustavo Dutra Cavalcanti
Gustavo Dutra Cavalcanti
MSMarcus Vinícius de Jesus Da Silva
Marcus Vinícius de Jesus Da Silva
GSGabriela Fonseca Saliba
Gabriela Fonseca Saliba
LVLucia Helena Ferreira Vasconcelos
Lucia Helena Ferreira Vasconcelos
DODanielle Furtado De Oliveira
Danielle Furtado De Oliveira
Nathalia Lopez DuarteNathalia Lopez Duarte
Nathalia Lopez Duarte
Objetivo: Relatar os efeitos do Canabidiol (CBD) na dor e em outros sintomas presentes em pacientes portadores de fibromialgia. Revisão bibliográfica: O CBD é um fitocanabinoide utilizado no tratamento de algumas patologias, dentre elas a fibromialgia. Ele interage com o sistema endocanabinoide por meio dos receptores CB1, CB2, e modula a atividade de outros ligantes e receptores. Estes, ao serem ativados pelo CBD, são dessensibilizados, o que reduz a percepção da dor em última análise. O CBD também interage com outros sistemas, afetando a resposta inflamatória. Pacientes com fibromialgia relatam dor intensa difusa, que também pode ser influenciada por metacognições. O CBD, como alternativa no tratamento dessa patologia, é capaz de modular a percepção de dor e, também, reduzir os sintomas depressivos nesses pacientes, melhorando a qualidade de vida dos mesmos, assim como traz outros benefícios a longo prazo. Considerações finais: O potencial terapêutico do CBD no tratamento da fibromialgia é evidenciado pela sua capacidade de interagir com o sistema endocanabinoide e outros mecanismos moleculares do cérebro humano, inibindo sintomas dolorosos. Assim, o CBD surge como uma alternativa segura com poucos efeitos colaterais no tratamento da fibromialgia, o que estimula a otimização de seu uso nesse perfil de pacientes.